Genentech, a member of the Roche Group, today announced an expansion of its initial investment in a new Holly Springs, North Carolina manufacturing facility. The increased investment will more than double the total commitment for the company’s first-ever East Coast manufacturing facility to approximately $2 billion.
The expansion builds on the company’s May 2025 investment announcement, as well as the project’s August 2025 groundbreaking.
The expanded investment allows Genentech to build out additional production capacity and increase the facility’s output. Set to be operational by 2029, the facility will produce treatments for metabolic conditions, such as obesity. By leveraging advanced biomanufacturing, automation, and digital tools, the investment will boost efficiency and sustainability while significantly expanding Genentech’s U.S.-based supply chain.
The expanded investment is expected to add an additional 100 new jobs to the North Carolina economy, with the project supporting more than 500 manufacturing jobs and 1,500 construction jobs.
This expansion supports Roche and Genentech’s broader $50 billion commitment to U.S. manufacturing. Roche and Genentech’s current U.S. footprint includes 13 manufacturing and 15 R&D sites across the company’s Pharmaceutical and Diagnostics Divisions and 25,000 employees in 24 sites across eight U.S. states.
